MedTrace Logo

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329

NCT01207089 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2011-05-10

No results posted yet for this study

Summary

The purpose of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8329 following multiple ascending dose administrations in in overweight to obese but otherwise healthy male subjects.

Conditions

Interventions

DRUG

AZD8329

AZD8329 Oral Solution 20mg/ml

DRUG

Placebo

Placebo AZD8329 Oral Solution

Sponsors & Collaborators

Principal Investigators

  • Dr. Jan Eriksson · AstraZeneca

  • Dr. Mirjana Kujacic · AstraZeneca

  • Dr. James Ritter · Quintiles Drug Research Unit at Guy's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01207089 on ClinicalTrials.gov